Repare Therapeutics (RPTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

RPTX Repare Therapeutics

Watchlist

3.370
-0.080-2.32%

Trading Oct 31 13:59 ET

143.04MMarket Cap-2067P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Repare Therapeutics Analyst Ratings
BenzingaOct 24 15:14 ET · Ratings
H.C. Wainwright Maintains Repare Therapeutics(RPTX.US) With Buy Rating, Maintains Target Price $10
Moomoo NewsOct 24 11:35 ET · Ratings
Repare Therapeutics Receives Buy Rating Due to Improved Treatment Tolerability and Promising Clinical Outcomes
TipRanksOct 24 11:25 ET · Ratings
TD Cowen Maintains Repare Therapeutics(RPTX.US) With Buy Rating
Moomoo NewsOct 24 08:31 ET · Ratings
Repare Therapeutics' Individualised Anaemia Management Trial Shows Promise
Yahoo FinanceOct 24 05:57 ET
Repare Therapeutics Presented Updated Data Highlighting The Benefits Of Its Individualized Schedule For Managing Anemia In Phase 1 MYTHIC Trial, Which Treated Patients With The Combination Of Lunresertib And Camonsertib
BenzingaOct 23 06:07 ET

Comments

Trytosaveabit

Oct 23 05:10

Update

$Repare Therapeutics (RPTX.US)$ Reuters· 4 mins ago
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results From the Phase 1 Mythic Clinical Trial

Trytosaveabit

Oct 14 06:11

Update

$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
5 MINUTES AGO, 7:05 AM EDT
VIA BUSINESSWIRE

Stock_Drift

Sep 30 15:16

After Hours Ticks, 4:14pm, EST.

$Mill City Ventures III (MCVT.US)$ $Jowell Global (JWEL.US)$ $NCI (01336.HK)$ $Onconetix (ONCO.US)$ $YXT.COM Group Holding (YXT.US)$ $Cognition Therapeutics (CGTX.US)$ $Ambow Education (AMBO.US)$ $Matinas BioPharma (MTNB.US)$ $TCTM Kids IT Education (TCTM.US)$ $N2OFF (NITO.US)$ $Repare Therapeutics (RPTX.US)$ $ZK International (ZKIN.US)$
📊⚡️📊

Jaguar8

Sep 30 15:12

NEWS

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Repare Therapeutics (Nasdaq: RPTX) presented Phase 1 data at the ASTRO Annual Meeting, showcasing the potential of camonsertib, an oral ATR inhibitor, combined with palliative radiation for treating metastatic tumors with ATM mutations.
The study enrolled 17 patients, 12 with pathogenic ATM mutations and 5 with va...